FDA Proposes Excluding GLP-1 Drugs From 503B Compounding List

Status update (Aug 19, 2026): The comment period closed July 30, 2026, and the FDA has issued no final determination on the proposed 503B exclusion of semaglutide, tirzepatide, and liraglutide. The decision now sits on the next FDA commissioner’s desk — Trump nominated Dr. Heidi Overton to lead the agency on Aug 19, and she has made no public statements on compounding. See what the Overton nomination means for peptide compounding and the 503A bulks list.

UPDATE (Aug 20, 2026): Novo has now formally asked the FDA to place semaglutide on the DDC lists, joining Lilly in the push to ban GLP-1 compounding outright. Full analysis: Compounded GLP-1 Ban: Novo and Lilly’s FDA Push Explained.

On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, “finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.” For the provider-side and regulatory picture, see our compounded GLP-1 ban explainer and the Fifth Circuit ruling analysis.

503B outsourcing facilities are the channel that compounded these drugs in bulk — without patient-specific prescriptions — at scale during the shortage era. The proposal would formalize the end of that pathway for all three molecules.

What the proposal says

The FDA’s press release stated there is “no clinical need for outsourcing facilities to compound these drugs from bulk substances.” The agency has taken the same position in successive waves of enforcement: semaglutide and tirzepatide are off the shortage list, branded supply has stabilized, and the shortage-era compounding pathway is closed.

The comment period was extended to July 30, 2026 (Federal Register 91 FR 23431) and has closed.

What happens next

The FDA has issued no final determination on the 503B rulemaking itself — but the underlying legal question is now settled: on Aug 27, 2026, the Fifth Circuit upheld the FDA’s shortage delisting, which already makes bulk compounding of semaglutide and tirzepatide for general use unlawful. The next commissioner — confirmed or acting — will still decide whether to finalize the 503B exclusion, modify it, or leave it unresolved; that call determines whether the ban persists even in a future shortage. The decision carries precedent for how the “clinical need” standard applies to peptides with thinner evidence bases, making it a direct signal for the broader compounding landscape.

Related coverage

• Overton FDA nomination: peptide compounding and the 503A bulks list
• FDA compounding pharmacy enforcement intensifies ahead of July PCAC
• FDA peptide enforcement timeline